A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma

NCT00792012 ↗

Phase 1 Completed 37 enrolled University of Colorado, Denver

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to find out the highest dose per fraction of hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) that can be safely given with temozolomide chemotherapy.

Timeline

Start: 2005-11
Primary completion: 2016-07
Completion: 2016-07

Publications

Reddy K, Damek D, Gaspar LE, Ney D, Waziri A, Lillehei K, Stuhr K, Kavanagh BD, Chen C. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):655-60. doi: 10.1016/j.ijrobp.2012.01.035. Epub 2012 Apr 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Temozolomide	Small molecule	75 mg/m2	Oral
Subject	Temozolomide	Small molecule	150 mg/m2	Oral
Subject	Temozolomide	Small molecule	200 mg/m2	Oral

A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma

Summary

Timeline

Publications

Drugs

Indications